Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNT-517 in Healthy Participants and in Participants With Phenylketonuria
NCT05781399Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of repinatrabit in phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2022; status: completed.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05781399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781399.